Evidence map›Paper›PMID 29086322›Full record

Trial reportJournal of assisted reproduction and genetics2018

A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.

Yanett Anaya, Douglas A Mata, Joseph Letourneau, Hakan Cakmak, Marcelle I Cedars, Mitchell P Rosen

Erratum issuedOpen access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of assisted reproduction and genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yanett AnayaCenter for Reproductive Health and Division of Reproductive Endocrinology and Infertility, University of California, San Francisco, 499 Illinois Street, San Francisco, CA, 94143, USA. yanett2121@gmail.com.ORCID http://orcid.org/0000-0003-2151-4652
Douglas A MataDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.
Joseph LetourneauCenter for Reproductive Health and Division of Reproductive Endocrinology and Infertility, University of California, San Francisco, 499 Illinois Street, San Francisco, CA, 94143, USA.
Hakan CakmakCenter for Reproductive Health and Division of Reproductive Endocrinology and Infertility, University of California, San Francisco, 499 Illinois Street, San Francisco, CA, 94143, USA.
Marcelle I CedarsCenter for Reproductive Health and Division of Reproductive Endocrinology and Infertility, University of California, San Francisco, 499 Illinois Street, San Francisco, CA, 94143, USA.
Mitchell P RosenCenter for Reproductive Health and Division of Reproductive Endocrinology and Infertility, University of California, San Francisco, 499 Illinois Street, San Francisco, CA, 94143, USA.
University of California, San Francisco · USBrigham and Women's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeModification of the trigger used to induce final oocyte maturation in in vitro fertilization (IVF) is a major strategy used to reduce the risk of ovarian hyperstimulation syndrome (OHSS). A novel trigger composed of 1500 IU of human chorionic gonadotropin (hCG) plus 450 IU of follicle-stimulating hormone (FSH) has been developed to reduce OHSS risk. This study compares outcomes of the novel trigger to conventional triggers used in high-risk OHSS patients undergoing IVF.

methodsIn this retrospective cohort study, IVF cycles at high risk for OHSS based on a serum estradiol > 5000 pg/ml on trigger day conducted between January 2008 and February 2016 were evaluated. Oocyte maturation was induced with the novel trigger (1500 IU hCG plus 450 IU FSH) or a conventional trigger [3300 IU hCG, gonadotropin-releasing hormone agonist (GnRHa) alone, or GnRHa plus 1500 IU hCG]. IVF cycle outcomes were compared. Trigger strategies were examined for associations with OHSS development using logistic regression.

resultsAmong 298 eligible IVF cycles identified, there were no differences in oocyte maturation, fertilization, embryo quality, or pregnancy outcomes among all triggers. After adjusting for serum estradiol level and number of follicles, the novel trigger was associated with lower odds of OHSS symptom development compared to the 3300 IU hCG and GnRHa plus hCG 1500 IU triggers (p = 0.007 and 0.04, respectively).

conclusionsThis study suggests that 1500 IU hCG plus 450 IU FSH may be associated with decreased OHSS symptoms compared to conventional triggers, while producing similar IVF and pregnancy outcomes. More important, this novel trigger may provide a superior alternative in down-regulated cycles and in patients with hypothalamic dysfunction where GnRHa triggers cannot be utilized.

Indexed as

AdultChorionic GonadotropinCryopreservationEmbryo TransferFemaleFertilization in VitroFollicle Stimulating HormoneHumansIn Vitro Oocyte Maturation TechniquesOocyte RetrievalOvarian Hyperstimulation SyndromePregnancyPregnancy OutcomePregnancy RateRetrospective StudiesTreatment OutcomeChorionic GonadotropinFollicle Stimulating HormoneFSH co-triggerhCG triggerIn vitro fertilization (IVF)Ovarian hyperstimulation syndrome (OHSS)

Identifiers

PMID29086322
PMCPMC5845042
OpenAlexW4241020023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.